alpha-synuclein drugs for Parkinson's Disease
5 tracked alpha-synuclein drugs in the Parkinson's Disease race. The class explanation lives on the alpha-synuclein page; the full indication pipeline across every mechanism is on the Parkinson's Disease page.
1 Phase 32 Phase 22 Phase 1
Head-to-head evidence: AFFITOPE PD01A / ACI-7104.056 vs UB-312 · AFFITOPE PD01A / ACI-7104.056 vs exidavnemab · LY3962681 vs UB-312 · exidavnemab vs LY3962681 · Prasinezumab vs UB-312 · exidavnemab vs Prasinezumab